Enzyme News and Research

RSS

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006

Gardenia fruit compound helps treat the symptoms of type 2 diabetes

A Gardenia fruit extract traditionally used in Chinese medicine to treat the symptoms of type 2 diabetes does indeed contain a chemical that reverses some of the pancreatic dysfunctions that underlie the disease, researchers report in Cell Metabolism.

6 Jun 2006

Discovery of protein associated with severe preeclampsia

Researchers have identified a second protein which, in combination with sFlt1, escalates preeclampsia to a severe - and life-threatening - state.

6 Jun 2006

Study confirms Gleevec's long-term benefits in treating advanced gastrointestinal stromal tumors

People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health & Science University Cancer Institute researchers.

6 Jun 2006

Sunitinib therapy shows promise in children with metastatic gastrointenstinal stromal tumor

Children with a rare digestive-tract cancer that is resistant to front-line therapy have benefited from a newer targeted therapy that has been shown effective in adults, according to data from a small pilot study.

5 Jun 2006

Sunitinib malate shows promise against advanced form of lung cancer

Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.

5 Jun 2006

Milstein gift seeks cure for antibiotic-resistant TB and malaria

A $7.25 million gift to Weill Medical College of Cornell University will establish the Abby and Howard P. Milstein Chemistry Core Facility and the Abby and Howard P. Milstein Program in Chemical Biology.

5 Jun 2006

Genes variations raise risk of heart disease after treatment for childhood cancer

Gene variations may raise the risk that survivors of childhood cancer will suffer congestive heart failure as a complication of drugs they received during cancer treatment.

5 Jun 2006

Molecular pathway may contribute to age related diseases

A common molecular denominator in aging and many age-related diseases is oxidative stress.

1 Jun 2006

Scientists gain better understanding of Proteus mirabilis

Scientists now have inside information to use in the fight against Proteus mirabilis - a nasty bacterium that can cause kidney stones, as well as hard-to-treat urinary tract infections.

1 Jun 2006

Blood pressure drugs associated with reduced risk of cancers

Thousands of individuals currently taking angiotension converting enzyme (ACE) inhibitors, a type of medication commonly used to lower blood pressure, may be doing more than treating their hypertension.

31 May 2006

COX-1 and COX-2 enzymes may be blocked by pain medications

COX-1 and COX-2 enzymes may be blocked by pain medications such as Advil and Vioxx in a more complex manner than was previously understood, a Queen's University study has found.

29 May 2006

Scientists map the entire active protein inventory in cells

Scientists have shown how cutting-edge methods can be used to catalogue the entire inventory of active proteins in cell organelles at a particular moment. Their work sheds considerable light on how cells use proteins.

29 May 2006

Cysteine containing tablets and chewing gum potential new way to prevent upper digestive tract cancers

Researchers at the University of Helsinki, Finland, suggest that cysteine containing tablets and chewing gum can be a new way for the prevention of upper digestive tract cancers.

23 May 2006

New study may advance treatments to prevent type 2 diabetes and metabolic syndrome

Insulin uses two distinct mechanisms to control glucose and the metabolism of blood fats (lipids) in the liver, a new Joslin Diabetes Center-led study has discovered.

23 May 2006

New antibiotic works against superbugs

A new antibiotic with the ability to fight drug-resistant superbugs has been developed by researchers at drug company Merck's research laboratories in New Jersey.

21 May 2006

Bedsores and bald hides: novel roles revealed for a "scaffolding" protein

A protein long thought to provide only mechanical support for keeping cells and tissues from literally falling apart turns out to have much wider utility.

17 May 2006

Sulforaphane shown to inhibit the occurrence of hereditary colon cancer

Need another reason to eat vegetables? A new study at Rutgers shows that certain vegetables - broccoli and cauliflower, in particular - have natural ingredients that may reduce the risk of developing hereditary cancers.

17 May 2006

Plasminogen activator inhibitor type 2 may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.

17 May 2006

New compound shows unique potency against cancer cell proliferation

By determining how a class of compounds blocks signaling in cells, University of California, San Francisco (UCSF) scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

16 May 2006